Skip to main content

Market Overview

Dicerna Starts Dosing With Nedosiran In Primary Hyperoxaluria Early-Stage Study

Share:
  • Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) initiates patient dosing in Phase 1 PHYOX 4 trial evaluating its lead candidate, nedosiran, to treat primary hyperoxaluria, a rare condition characterized by the recurrent kidney and bladder stones. The condition often results in end-stage renal disease.
  • The study will evaluate the safety and efficacy of a single dose of nedosiran and assess the proportion of participants achieving more than a 30% decrease from baseline in 24-hour urinary oxalate on two consecutive visits.
  • The trial is expected to enroll six participants aged six years and above, and results are expected in mid-2021.
  • PHYOX4 participants who respond to treatment with nedosiran and complete the trial are eligible to enroll in the Company's PHYOX3 trial, an ongoing open-label extension study evaluating nedosiran's long-term safety and efficacy.
  • Nedosiran marketing application submission is anticipated in the third quarter of 2021.
  • Price Action: DRNA moved 0.46 higher at $26 during market hours on the last check Thursday.
 

Related Articles (DRNA)

View Comments and Join the Discussion!

Posted-In: Phase 1 Trial Primary HyperoxaluriaBiotech News Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com